The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients.

Anemia · 2015 · PMC4710935 · PMID 26843983

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Also, low dose requirement in CERA phase can be explained by an increase in iron use in terms of proportion of patients receiving iron, serum ferritin, TSAT, and mean iron doses, but this improvement did not reach statistical significance in comparison to EpoB period.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.